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CASE PRESENTATION
A 62-year-old white male, with a bipolar disorder treated
with lithium, a history of type II diabetes mellitus, and
hypertension, was referred to the renal clinic for
evaluation of nephrotic syndrome and stage IV chronic
kidney disease (CKD) (Modification of Diet in Renal Disease
glomerular filtration rate 26 cc/min/1.73 m2). The patient
had a history of bipolar disorder treated for over 10 years
with lithium until 2 years ago when a diagnosis of
nephrogenic diabetes insipidus and mild CKD was made
and lithium discontinued. At that time, he had a urine
osmolality of 272 mOsm/kg and a serum creatinine of
1.5 mg/dl. His medications included lisinopril, atenolol,
gemfibrozil, haloperidol, quetiapine, metformin, and
bupropion SR. There was no history of polyuria or
polydipsia. Review of systems revealed no other
significant symptoms. On examination, blood pressure
was 133/64 mm Hg, heart rate 70 beats per minute,
regular rhythm. Lung and cardiovascular examination
were unremarkable. Abdomen was soft, nontender with
no organomegaly. Extremities revealed trace edema. Urine
examination revealed a specific gravity of 1.012, pH 5.5,
3þ protein, negative blood and no casts. His urine
albumin creatinine ratio 3 months before was 3.9 g
protein per gram creatinine. His laboratory investigations
revealed BUN 40 mg/dl (reference range 9–25 mg/dl),
creatinine 3.0 mg/dl (0.7–1.3 mg/dl), potassium 5.6 mEq/l
(3.5–5.0 mmol/l), glucose 72 mg/dl (5–118 mg/dl), HbA1C
4.8 (4.2–5.8%), serum total proteins 6.2 g/dl (6–8 g/dl),
albumin 3.5 g/dl (3.7–5.4 g/dl), cholesterol 208 mg/dl
(140–199 mg/dl), triglycerides 626 mg/dl (35–150 mg/dl),
low-density lipoprotein 78 mg/dl (50–129 mg/dl),
hemoglobin 13.2 g/dl (11.5–16.4 g/dl), and hematocrit
of 37.7% (36–48%). Complements and other serologic
tests were negative. Renal ultrasound revealed bilateral
nephromegaly (right kidney 12.6 cm and left kidney
12.9 cm) with a diffuse increase in echogenicity and
innumerable tiny cysts throughout the kidney (cortex and
medulla) (Figure 1). There was no evidence of
hydronephrosis. A clinical diagnosis of nephrotic
syndrome was made and it was decided to proceed to a
kidney biopsy.
KIDNEY BIOPSY
On light microscopy, 16 glomeruli were observed. Seven
(44%) were globally sclerosed and two revealed segmental
capillary collapse, with hyaline entrapment and adhesion of
the tuft to the Bowman’s capsule (Figure 2). The remaining
glomeruli showed a normal architecture, with mild mesangial
hypercellularity associated with diffuse increase in the
extracellular matrix. The glomerular basement membranes
revealed focal irregularities and short segments with double
contours. Tubules revealed extensive atrophy (45%) with
thickening of tubular basement membranes. Many micro
cysts, ranging in size from 1 to 2 mm, were noted. These were
localized in the cortex and along the corticomedullary
junction. The lining was of low cuboidal epithelial cells.
Pericystic stromal fibrosis was apparent (Figure 3). Focal
calcification and protein reabsorption granules were also
noted in many tubules. The interstitium showed prominent
areas of fibrosis (45%) and interstitial inflammation by
mononuclear cells and very rare polymorphonuclear cells.
Interlobular arteries and arterioles revealed moderate changes
of arteriosclerosis. Congo-red stain was negative. No
significant deposits were observed on immunofluorescence
microscopy, except for nonspecific trapping of immunoglobulin
M and C3 in the mesangial areas. Tubular basement membranes
revealed focal deposition of C3 (þ þ þ /4þ ). A single
sclerosed glomerulus was observed on semithin sections hence
the tissue was not examined at ultrastructural level.
A biopsy diagnosis of chronic active interstitial nephritis
likely secondary to lithium toxicity was made. The presence
of numerous cortical micro cysts and the focal global and
segmental glomerulosclerosis (FSGS) were also attributed to
lithium.
CLINICAL FOLLOW-UP
The patient’s psychoactive medications were continued. The
management of the nephrotic syndrome included escalation
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of his lisinopril dose. However, at the last follow-up, the
patient’s kidney function as measured by serum creatinine
was 3.52 mg/dl with an estimated Modification of Diet in
Renal Disease glomerular filtration rate of
18 ml min1 1.73 m2. His urine protein to creatinine ratio
was 5.4 g protein per gram creatinine.
DISCUSSION
Chronic forms of lithium toxicity include renal tubular
acidosis, chronic tubulointerstitial nephritis, and nephrotic
syndrome. Our patient illustrates many of these changes. He
developed nephrogenic diabetes insipidus (NDI) following
lithium therapy, which was subsequently complicated by the
development of chronic progressive kidney disease; this
necessitated the discontinuation of lithium. The patient also
presents with the nephrotic syndrome, most likely secondary to
FSGS, as a consequence of lithium exposure. His kidney biopsy
revealed the presence of extensive chronic interstitial nephritis,
tubular microcystic structures in the renal cortex and FSGS that
are characteristic, but not specific for lithium toxicity.
Lithium carbonate is a valuable therapeutic agent in the
treatment of manic-depressive illness. It continues to be
widely used. However, lithium has a narrow therapeutic
index and can result in considerable toxicity. Both acute and
chronic forms of renal toxicity are well-known complica-
tions.1,2 The major complications of lithium toxicity are
discussed.
Nephrogenic diabetes insipidus
The first report of lithium toxicity in humans was made by
Edgell et al.2 approximately 3 decades ago. The most
common early complication of chronic lithium ingestion is
NDI, which is observed in approximately 20% of patients.1
NDI occurs because of lithium accumulation in collecting
tubule cells through entry of lithium via sodium channels in
the luminal membrane.3 Lithium interferes with the ability of
antidiuretic hormone to increase water permeability. Several
mechanisms have been postulated, including decreased
stimulation of adenylate, reduced density of antidiuretic
hormone receptors, and a downregulation of aquaporin-2,
the collecting tubule water channel.4–7 The progression of the
renal concentrating deficit is usually observed early—within
the first few years of treatment.8 Although it has been
suggested that the lesion of lithium-induced tubular toxicity
is reversible in its earliest stages,1 there is a ‘point-of-no-
return’ after which injury becomes irreversible.9,10 Our
patient developed irreversible damage from lithium as
evidenced by the persistent clinical abnormalities and the
findings on his renal biopsy.
Figure 1 | Renal ultrasound of left kidney displays several simple
cysts. The overall increase in echogenicity is likely secondary to
innumerable tiny cysts, consistent with prior lithium use.
Figure 2 | Segmental glomerular sclerosis with collapse of the
capillary tufts and intracapillary foam cells was noted in a few
glomeruli (PAS  400).
Figure 3 | Tubular cysts lined by lowered cuboidal epithelial cells
are seen in a stroma, which has much fibrosis (PAS  200).
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Lithium associated chronic tubulointerstitial nephritis
Chronic lithium-induced tubulointerstitial nephritis is charac-
terized by the presence of tubular atrophy and interstitial
fibrosis.11 Chronic interstitial changes on renal biopsy have
been described even following acute intoxication or NDI.12
The presence of tubular cysts, as observed with our patient, is
highly characteristic of lithium toxicity.13 Markowitz et al.11
documented cysts in 62.5% of the biopsies studied and
confirmed, in elegant immunohistochemical and lectin
studies, that the tubular cysts are predominantly of distal
and collecting tubular origin. These micro cysts can also be
detected using magnetic resonance imaging or ultrasound.
Indeed, in their magnetic resonance imaging study of 16
patients on long-term lithium therapy, Farres et al.14 have
demonstrated abundant, uniform, symmetrically distributed
renal micro cysts in normal-sized kidneys. In our patient,
micro cysts were observed by ultrasound in relatively large
kidneys (Figure 1).
Lithium induced glomerular damage
Proteinuria is an uncommon manifestation of lithium
toxicity and is usually not severe (24-h protein excretion
o1 g day1).15 Lithium-induced nephrotic syndrome has
been reported but is rare, with only 26 cases reported in
the literature.11,15–18 The mechanism of injury is thought to
be lithium-induced epithelial toxicity, resulting in either
minimal change disease or secondary FSGS. Minimal change
disease is more common than FSGS.19 Tam et al.20 have
invoked a role for lithium as a modulator of the
phosphoinositol pathway in the pathogenesis of minimal
change disease following lithium therapy. In some patients
with minimal change disease, resolution after discontinua-
tion of lithium therapy and relapse after re-introduction of
lithium has been reported, showing a causative link with
lithium therapy.21 FSGS in patients following chronic lithium
therapy has also been reported in the literature.11,15,16
Markowitz et al.11 have described FSGS in 50% of their 24
cases. Glomerulomegaly and a variable degree of foot process
fusion is a consistent finding. A higher prevalence of
glomerular changes correlated with a higher prevalence of
proteinuria. Significant proteinuria (43 g day1) was ob-
served in 6 of the 24 (25%) and nephrotic syndrome in three
patients (12.5%). In the patient we present here, we were
unable to definitively evaluate the degree of podocyte injury
because insufficient material was available for ultrastructural
examination. Therefore, we cannot say for sure whether this
patient truly had secondary FSGS either from direct damage
by lithium or hyperfiltration injury, or whether he had a
primary form of FSGS.
Lithium and chronic kidney disease
Lithium’s role as a causal agent in progressive chronic kidney
disease (CKD) is controversial. Johnson22 suggests that
lithium-induced CKD is rare. Coskunol et al. compared
107 subjects on lithium therapy with a matched psychiatric
control population. They found no relationship between
creatinine clearances and duration of illness, duration of
lithium treatment and daily lithium dosages.23 Boton et al.,1
from their analysis of several published studies, estimated
that 15% of patients displayed only mild reduction in
glomerular filtration rate. Hansen et al.13 reported an
increase in serum creatinine of 40.3 mg/dl in eight patients
treated with lithium for at least 4 1/2 years. Jorkasky et al.24
have reported a significant decline in renal function within 1
year of therapy in their prospective study of lithium-induced
nephropathy. Presne et al.25 have demonstrated the annual
loss of creatinine clearance in patients to be 2.9 ml min1
among 54 patients with lithium-induced nephropathy, and
claimed that the renal disease was slowly progressive and was
related to the duration of lithium administration. Markowitz
et al.11 observed a high prevalence of CKD in the 24 subjects
in their study (mean serum creatinine of 2.8 mg/dl, range
1.3–8 mg/dl) and found that serum creatinine at the time of
biopsy was the only reliable predictor of progression to end-
stage renal disease. In their study, progression of kidney
disease to end-stage renal disease was observed in 8 of 9
patients with serum creatinine 42.5 mg/dl at the time of
diagnosis as compared to 1 of 10 patients with a serum
creatinine o2.5 mg/dl.
Lithium dosing and kidney function
Different treatment regimes have been evaluated. Once-daily
regimes appear to be less toxic than multiple-daily dose
schedules,26,27 perhaps because of the possibility of renal
tubular regeneration with a once-daily dosing schedule. On
the other hand, patients who have switched from one regime
to another have not demonstrated a significant change in
tubular function, except when the switch occurred within less
than 5 years of treatment.28 Other risk factors for kidney
progression include age, episodes of lithium intoxication, and
current drug administration.29 The concomitant presence of
co-morbid disorders such as hypertension, mitral valve
insufficiency, hyperparathyroidism, hyperuricemia, diabetes
have also been reported to be important.9,10,30 Aggravation of
diabetic nephropathy by lithium has also been reported.31
The concomitant use of other anti-psychotic drugs in
exacerbating lithium-induced injury has been discussed in
the literature.10,32
Acute lithium intoxication. Acute lithium intoxication is a
frequent complication of chronic lithium therapy because of
its narrow therapeutic index. It is critical to recognize the
clinical manifestations of acute lithium toxicity because the
mortality rate is reported to be approximately 25% in an
acute overdose and 9% in patients intoxicated during
maintenance therapy.33 Since lithium primarily undergoes
renal excretion, factors that affect glomerular filtration rate
and reabsorption play an important role in maintaining
serum lithium levels. Patients with lithium intoxication may
present with a variety of clinical manifestations, including
gastrointestinal, cardiac, renal, endocrine, and neurological
symptoms. Neuropsychiatric symptoms are particularly
common: characteristic findings include neuromuscular
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excitability, irregular coarse tremors, fascicular twitching,
rigid motor agitation, muscle weakness, ataxia, sluggishness,
and delirium. Non-neurologic presenting features include
nausea, vomiting, diarrhea, leukocytosis, sinus bradycardia,
and hypotension. Severe lithium intoxication can result in
seizures, stupor, coma, and a 10% risk of permanent
neurologic sequelae (such as dementia and ataxia). Kidney
manifestations include polyuria and polydipsia, which is
important pathogenically as polyuria may lead to volume
depletion and decreased fractional excretion of lithium.
Management of lithium therapy and toxicity
A multifaceted approach to the management of lithium
therapy is essential—prevention of toxicity as well as treating
those who develop NDI. Strategies to reduce the risk of
lithium toxicity include careful lithium dosing with regular
monitoring of blood levels. This is especially important since
lithium has a narrow therapeutic index and toxicity has been
observed even among those patients at supposedly therapeu-
tic doses. Therapeutic levels of lithium are between 0.6 and
1.2 mEq/l. Mild toxicity with lithium is usually observed at a
plasma lithium level of 1.5–2.5 mEq/l and moderate toxicity
at lithium levels of 2.5–3.5 mEq/l. Another important
component of preventing lithium toxicity is to carefully
monitor patients; in this regard, looking for symptoms of
polyuria and excessive thirst and assessment of kidney
function, urine volume, and/or urine osmolality are im-
portant. Finally, preventing volume depletion is important in
reducing the risk of lithium toxicity. Bendz and Aurell34
suggest monitoring plasma lithium and plasma creatinine
assessment every 4 months. Thyroid and parathyroid
function, weight, 24 h consumption of liquids (24-h urine
output), blood glucose and blood pressure are be monitored
annually. These authors also recommend testing for tubular
and glomerular functions every 5 years while the patient is on
lithium therapy and when clinically indicated.
The treatment of an acute intoxication from any drug
requires rapid evaluation, including the recognition that
poisoning has occurred, identification of the agents involved,
assessment of severity, and prediction of toxicity. Manage-
ment, consisting of supportive care, prevention of drug
absorption, and, when appropriate, the administration of
antidotes and enhancement of drug elimination is critical.
The key aspects of managing acute lithium toxicity include
aggressive volume resuscitation, gastric lavage with poly-
ethylene glycol to prevent the continued absorption of
lithium, and hemodialysis. Hemodialysis is generally indi-
cated in two clinical scenarios: a plasma lithium level
44 mEq/l, regardless of the clinical status of the patient,
and the plasma lithium concentration 42.5 mEq/l in a
patient who is markedly symptomatic or with underlying
CKD that might limit urinary lithium excretion.33,35
In the treatment of NDI, lithium discontinuation is
recommended; however, the lithium-concentrating defect
may be permanent after prolonged lithium usage. Slowing
progression using an angiotensin blocker, control of blood
pressure, and avoiding other nephrotoxins are also recom-
mended. (The use of amiloride should be considered in those
patients where lithium therapy cannot be discontinued.)
Conclusions
The patient we have presented highlights several unusual
features associated with lithium therapy: chronic tubulo-
interstitial nephritis and microcystic changes, nephrotic range
proteinuria with associated focal and global glomerulosclero-
sis, and the presence of CKD. Lithium toxicity can present
with several faces: acute abnormalities from lithium poison-
ing and chronic changes such as NDI, epithelial cell disease,
and CKD. While lithium is a boon in the management of
bipolar disorders, it has unfortunately undesirable side effects
and lithium therapy could be likened to a ‘double-edged
sword—it cuts both ways.’
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